This study evaluated the impact of calcium and magnesium on the in vitro degradation and in vivo clearance of oxaliplatin. Intact oxaliplatin and Pt(DACH)Cl 2 were measured in incubation solutions by HPLC-UV. A clinical study determined changes in plasma concentrations of calcium and magnesium in cancer patients and their impact on oxaliplatin clearance. Kinetic analyses modelled oxaliplatin degradation reactions in vitro and contributions to oxaliplatin clearance in vivo. Calcium and magnesium accelerated oxaliplatin degradation to Pt(DACH)Cl 2 in chloride-containing solutions in vitro. Kinetic models based on calcium and magnesium binding to a monochloro-monooxalato ring-opened anionic oxaliplatin intermediate fitted the in vitro degradation time-course data. In cancer patients, calcium and magnesium plasma concentrations varied and were increased by giving calcium gluconate and magnesium sulfate infusions, but did not alter or correlate with oxaliplatin clearance. The intrinsic in vitro clearance of oxaliplatin attributed to chloride-, calcium-and magnesium-mediated degradation predicted contributions of <2.5% to the total in vivo clearance of oxaliplatin. In conclusion, calcium and magnesium accelerate the in vitro degradation of oxaliplatin by binding to a monochloro-monooxalato ring-opened anionic intermediate. Kinetic analysis of in vitro oxaliplatin stability data can be used for in vitro prediction of potential effects on oxaliplatin clearance in vivo.
also been suggested that oxaliplatin and/or its metabolites may increase calcium influx into the cytosol of peripheral neurons, which in turn may enhance the activation of sodium and potassium channels, calcium regulated transcription factors and intracellular signalling involving calcium-dependent protein kinases 20, 21 . On the basis of a retrospective clinical study suggesting neuroprotective effects of calcium gluconate and magnesium sulfate (CaGluc/MgSO 4 ) infusions given concurrently with oxaliplatin therapy 22 and supporting preclinical data 23 , these infusions became routinely used without further confirmatory prospective randomised trials or evaluation of any potential pharmacokinetic interactions with oxaliplatin. Since 2013, after two prospective randomised trials definitively showing a lack of neuroprotective effects of these infusions against both acute and chronic forms of oxaliplatin neurotoxicity 24, 25 , they are now commonly omitted from the routine clinical practice 26 .
The potential impact of calcium and magnesium on the in vitro degradation and in vivo clearance of oxaliplatin was previously unknown. Once administered oxaliplatin has been proposed to undergo rapid non-enzymatic biotransformation reactions with water and nucleophiles such as chloride, methionine and glutathione [27] [28] [29] . It is not known to be subject to CYP-P450 mediated metabolism. The initial reaction in oxaliplatin biotransformation can involve displacement of the oxalate group by water and chloride, resulting in formation of reactive species such as monochloro-, dichloro-, and diaquo-DACH platinum, where DACH is the common abbreviation for cyclohexane-1,2-diamine 29 . Initial degradation of oxaliplatin in the presence of chloride in vitro was previously suggested to lead to formation of an intermediate species, monochloro-monooxalato ring-opened complex, [Pt(DACH)oxCl] −30 (Fig. 1 ). This complex can convert back to oxaliplatin or transform into the final product, Pt(DACH)Cl 2 , resulting in overall slow degradation of oxaliplatin. The contributions made by these different ligand displacement reactions to the in vivo clearance of oxaliplatin are not well understood. To date, there have been few previous attempts to apply in vitro -in vivo extrapolation methods to predicting effects on the in vivo clearance of oxaliplatin. In drug discovery, techniques for predicting in vivo clearance of drugs using in vitro drug metabolism kinetic data has been used, particularly in vitro hepatocyte or microsomal metabolic stability kinetic data for predicting hepatic clearance of drugs in vivo 31, 32 . For drugs, such as oxaliplatin, that are not metabolised by the liver, there is little literature available about the prediction of in vivo clearance using in vitro kinetic data.
With this background, we sought to evaluate the potential impact of calcium and magnesium on the in vitro degradation and the in vivo clearance of oxaliplatin. Drug stability studies and kinetic modelling were used to explore reactions of oxaliplatin and its degradation products with calcium and magnesium in vitro. A clinical study was undertaken to determine changes in plasma concentrations of calcium and magnesium in cancer patients given oxaliplatin with or without infusions of calcium gluconate and magnesium sulfate, and their impact on oxaliplatin clearance. These in vitro and clinical datasets provided an opportunity to develop and exemplify experimental approaches for prediction of effects on oxaliplatin clearance in vivo from oxaliplatin stability data generated in vitro.
Results
In vitro degradation of oxaliplatin. To evaluate the potential impact of calcium and magnesium on the in vitro degradation of oxaliplatin, oxaliplatin was incubated in water and solutions containing NaCl, CaCl 2 and MgCl 2 at 37 °C for 8 hours. Incubation samples were collected and analysed using a validated HPLC-UV method 33 to determine oxaliplatin and Pt(DACH)Cl 2 concentrations at pre-defined time points over the incubation period. Data were presented as plots of concentration versus time and the mass balance of the reaction (Fig. 2 ). Oxaliplatin was unstable in the presence of chloride and degraded to Pt(DACH)Cl 2 via an intermediate Kinetic analysis of in vitro degradation. The kinetic model proposed by Jerremalm et al. 29, 30 for the stepwise reaction of oxaliplatin with chloride, comprising of a reversible first step producing [Pt(DACH)oxCl] − followed by an irreversible second step producing Pt(DACH)Cl 2 (Fig. 1) , was fitted to the mean measured concentration values obtained at time points during the in vitro degradation studies. Rate constants ( Table 1) were obtained by least-squares fitting to the analytical expressions shown below (Equations (1-5) for the reaction scheme in Fig. 1 to the three species simultaneously 34 . Standard errors for the rate constants were derived from a Jack-knife procedure 35 . The parameters λ 1 and λ 2 are the observed biexponential decay constants, and are combinations of the rate constant for oxalate ring opening k 1 , the rate constant for ring closing k −1 , and the rate constant for oxalate loss k 2 . The kinetic models fitted the experimental data for all conditions (Fig. 2 ). Addition of CaCl 2 or MgCl 2 increased the observed rate of degradation of oxaliplatin and caused increased amounts of the intermediate species to form. However, analysis of the data showed that the k 1 rate constants for the oxalate ring opening step in the oxaliplatin degradation reaction were similar in 150 mM NaCl, 75 mM CaCl 2 and 75 mM MgCl 2 , while the k −1 rate constants for the back reaction corresponding to oxalate chelate ring closing and reformation of oxaliplatin from the [Pt(DACH)oxCl] − intermediate were decreased in 75 mM CaCl 2 and 75 mM MgCl 2 as compared to 150 mM NaCl. Finally, the values for the k 2 rate constant for the loss of the monodentate oxalate ligand from [Pt(DACH) oxCl] − leading to formation of Pt(DACH)Cl 2 were increased in 75 mM CaCl 2 and 75 mM MgCl 2 as compared to 150 mM NaCl. Thus, the observed increase in degradation is not due to an increased rate of the initial oxalate ring opening, but rather is due to a combination of a decrease in the reverse rate of oxalate ring closure combined with an increase in the rate of loss of oxalate.
These findings suggested that calcium and magnesium did not interact significantly with oxaliplatin at the concentrations studied, but bound to the monodentate oxalate-containing complex [Pt(DACH)oxCl] − , and in doing so, decreased the rate of oxalate ring closure and increased the rate of loss of oxalate from the ring-opened intermediate. The kinetics of the reaction mechanism were therefore modelled further by including an additional metal bonded intermediate species as shown in the shaded area of Fig. 1 . With the assumption that the rate constant for the reformation of oxaliplatin from the metal bonded intermediate (k 
Plasma calcium and magnesium concentrations after CaGluc/MgSO 4 infusions in patients. The
in vitro findings described above suggested that calcium and magnesium may alter the in vivo clearance of oxaliplatin by accelerating its degradation via binding to [Pt(DACH)oxCl] − . Plasma calcium and magnesium concentrations vary between patients, on different occasions, and are altered in the presence of cancer, associated disease processes and treatments 36, 37 . Until recently, CaGluc/MgSO 4 infusions had been routinely given concurrently with oxaliplatin for the purpose of limiting neurotoxicity 26 but their effects on oxaliplatin clearance or plasma calcium and magnesium levels had not been well studied. In a randomised placebo-controlled crossover clinical study, we sought to understand how variation in plasma calcium and magnesium concentrations, and the administration of CaGluc/MgSO 4 infusions, influenced oxaliplatin clearance in cancer patients receiving chemotherapy, by measuring plasma concentrations of calcium and magnesium before and after CaGluc/MgSO 4 and placebo infusions given with oxaliplatin. We previously reported that oxaliplatin clearance was not altered by giving CaGluc/MgSO 4 infusions 24 . The mean oxaliplatin clearance was 35.3 L/hr (SD 9.8) with CaGluc/MgSO 4 infusions and 33.6 L/hr (7.7) with placebo infusions (p = 0.17). Here we report that plasma concentrations of calcium and magnesium were significantly higher after the first CaGluc/MgSO 4 infusions than at baseline (calcium 1.04-fold increase, p < 0.001; magnesium 1.2-fold increase, p < 0.001) ( Fig. 3 ). Plasma calcium concentration had returned to near baseline levels immediately prior to the second CaGluc/MgSO 4 infusion two hours later but increased again after the second infusion (1.09-fold increase, p < 0.001). Plasma magnesium concentration, however, remained significantly higher (1.13-fold increase, p < 0.001) than baseline when the second infusion was due and were increased further following the second infusion (1.5-fold increase, p < 0.001). There were no significant changes in plasma calcium and magnesium levels after the placebo infusions.
Oxaliplatin clearance values measured on treatment cycles given with CaGluc/MgSO 4 or placebo infusions were plotted against their corresponding maximal plasma calcium and magnesium levels for each study patient ( Fig. 4 ). Maximum plasma concentrations of calcium and magnesium were within normal limits after placebo infusions. After CaGluc/MgSO 4 infusions, however, maximum plasma levels exceeded the upper limit of normal in 4 (21%) and 19 (100%) patients for calcium and magnesium, respectively. According to Common Toxicity Criteria Adverse Effect version 4.0 grading, elevated plasma calcium were severity grade 1 in 3 patients (16%) and grade 2 in 1 patient (5%), while elevated plasma magnesium was severity grade 1 in 12 patients (63%) and grade 3 in 7 patients (37%). Pearson co-efficient correlation analysis showed that oxaliplatin clearance did not correlate with plasma calcium (p = 0.33) or magnesium (p = 0.60) concentrations.
In vitro Prediction of calcium-, magnesium-and chloride-mediated clearance of oxaliplatin.
To estimate potential contributions of calcium-, magnesium-and chloride-mediated degradation to the in vivo clearance of oxaliplatin in patients, an in vitro -in vivo extrapolation method was developed. First, the in vitro intrinsic clearances of oxaliplatin attributable to calcium-, magnesium-and chloride-mediated degradation were calculated. Non-compartmental analysis was used to calculate the AUC 0−infinity for oxaliplatin concentration versus time for each experimental condition. Then the total in vitro clearance of oxaliplatin for each condition was obtained by dividing the amount of oxaliplatin added to the solution per unit volume by the AUC 0−infinity . Oxaliplatin clearance attributable to calcium-or magnesium-mediated degradation was then calculated by subtracting the clearance attributable to chloride from the total in vitro clearance value for the relevant experimental condition. Calculated values for oxaliplatin clearance attributable to chloride, calcium and magnesium were then plotted against the concentrations of the relevant ion in the incubation solution and analysed by linear regression. The in vitro intrinsic clearance attributable to chloride, calcium and magnesium was taken from the slope of the linear regression fit to its data as shown in Table 2 and Supplementary Figure. These data were then scaled to the in vivo setting by calculating the total extracellular fluid (ECF) content of calcium, magnesium and chloride from estimates of ECF volume and measured plasma concentrations of these ions in patients from our clinical study. In vivo clearance predictions were then made by multiplying the in vitro intrinsic clearance value by the calculated ECF content value of each ion.
The in vitro intrinsic clearance of oxaliplatin attributable to calcium-, magnesium-and chloride-mediated degradation was calculated to be 0.0039, 0.0023 and 0.00037 L/hr/mmol, respectively ( Table 3 ). The predicted in vivo oxaliplatin clearances attributable to calcium, magnesium and chloride were 0.15 L/hr, 0.03 L/hr and 0.68 L/ hr, respectively, before CaGluc/MgSO 4 infusions. After the CaGluc/MgSO 4 infusion, these predicted in vivo oxaliplatin clearance values increased slightly to 0.16 L/hr for calcium and 0.05 L/hr for magnesium but remained unchanged for chloride. The combined oxaliplatin clearance attributable to the sum of calcium-, magnesium-and chloride-mediated degradation was predicted to be 0.86 and 0.89 L/hr before and after CaGluc/MgSO 4 infusions, respectively. Considering the total in vivo clearance of oxaliplatin measured in our clinical study (35.3 L/hr), calcium-, magnesium-and chloride-mediated degradation was predicted to account for less than 2.5% of the total clearance of oxaliplatin in vivo.
Discussion
This study showed that calcium and magnesium accelerate oxaliplatin degradation by binding to the monochloro-monooxalato ring-opened anionic oxaliplatin intermediate, [Pt(DACH)oxCl] − , that forms in chloride-containing physiological solutions in vitro. To our knowledge, calcium and magnesium have not been previously reported to alter oxaliplatin degradation or bind to its degradation intermediates. We showed that the in vitro degradation of oxaliplatin to Pt(DACH)Cl 2 was faster in the presence of calcium and magnesium by directly quantifying both intact oxaliplatin and Pt(DACH)Cl 2 using HPLC-UV. Mass balance analysis revealed a deficit after accounting for these two compounds consistent with the transient formation of an intermediate species. Further evidence came from kinetic analyses and rate constants calculated for the reaction scheme in Fig. 1 suggesting that calcium and magnesium interacted with the oxalate ring-opened anionic oxaliplatin intermediate, [Pt(DACH)oxCl] − , resulting in a decreased rate of oxalate ring closure, and an increased loss of monodentate oxalate leading to formation of Pt(DACH)Cl 2 . Oxaliplatin was unstable in the presence of chloride as previous reported by Jerremalm et al. 30 but our findings also provide a mechanism of how calcium and magnesium influence this process of oxaliplatin degradation. This new information may have important implications for understanding how oxaliplatin behaves under in vivo conditions when other reactants or cations are present. This current study provides a new experimental approach for predicting effects on the in vivo clearance of oxaliplatin from in vitro studies of oxaliplatin degradation. It is, to our best knowledge, the first time that in vitro -in vivo extrapolation methods have been applied to predicting effects on oxaliplatin clearance. The concept was based on methods which are already established for in vitro -in vivo prediction of drug clearance mediated by hepatic microsomal metabolism by CYP-P450 and other enzymes, and which are commonly used in pre-clinical studies of the metabolic stability of new chemical entities 32 . However, oxaliplatin is not subject to hepatic metabolism, but degrades via leaving group displacement reactions, although little is known about their contributions to the in vivo clearance of oxaliplatin. To estimate effects on the in vivo clearance of oxaliplatin, we first obtained experimentally determined values for the in vitro intrinsic clearance of oxaliplatin attributable to calcium-, magnesium-and chloride-mediated oxaliplatin degradation, calculated from kinetic analyses of in vitro oxaliplatin stability data. Then, scaling factors were used to estimate the contributions of these processes to the in vivo clearance of oxaliplatin. This experimental approach has potential for providing new insights into mechanisms of oxaliplatin clearance. Previously, for example, it was suggested that oxaliplatin may initially react with water or chloride during its in vivo biotransformation 28, 29 . However, we found oxaliplatin to be stable in water in vitro, and that chloride-mediated oxaliplatin degradation was predicted to contribute only 1.9% to the total in vivo clearance of oxaliplatin. This stability of oxaliplatin in pure water or in chloride may be due to slow oxalate ring opening and/or fast oxalate ring closing. These findings suggest that oxaliplatin degradation mediated only by water or chloride may contribute less than previously thought to the total clearance of oxaliplatin in vivo, as suggested by a low formation of Pt(DACH)Cl 2 from oxaliplatin under in vivo conditions 24, 38 .
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In cancer patients receiving oxaliplatin chemotherapy, we found that plasma calcium and magnesium concentrations were increased significantly after the infusions of calcium gluconate and magnesium sulfate given immediately before and after oxaliplatin chemotherapy. These infusions were, until recently, routinely used in the clinic for the purpose of reducing neurotoxicity. Statistically significant increases in plasma calcium and magnesium occurred following each of the two CaGluc/MgSO 4 infusions. Post-infusion elevations in plasma calcium were CTCAE severity grade 1 in three patients and grade 2 in one patient, while elevations in plasma magnesium were CTCAE grade 1 in twelve patients and grade 3 in seven patients. There has not been a previous study, which we are aware of, showing these effects on plasma calcium and magnesium levels in patients immediately or soon after these infusions prior to this current study. In our study, plasma calcium and magnesium levels were measured only at baseline, 20 minutes after the first CaGluc/MgSO 4 infusions and immediately after the second CaGluc/ MgSO 4 infusion. We did not fully evaluate the time-course, duration, extent or clinical safety concerns related to these treatment-associated elevations in plasma calcium and magnesium levels. Previously, Gamelin et al. 39 reported no difference in plasma calcium and magnesium levels after the end of oxaliplatin infusion given without CaGluc/MgSO 4 infusions. Their reported values were very similar to those found in the current study at baseline or after placebo infusions. This clinical study also provided an opportunity to explore potential relationships between plasma calcium and magnesium levels and the clearance of oxaliplatin. Plasma calcium and magnesium varied widely between different patients and treatment cycles but did not correlate with oxaliplatin clearance. This finding was in keeping with the in vitro prediction that calcium-and magnesium-mediated degradation contributed a relative small amount (<2.5%) to the total in vivo clearance of oxaliplatin.
The method we describe for the in vitro prediction of effects on the in vivo clearance of oxaliplatin could assist with translating new treatments to clinical evaluation for preventing oxaliplatin neurotoxicity. Many new candidate treatments for preventing neurotoxicity of oxaliplatin are being identified by preclinical studies, for example, L-type calcium channel blockers 20 and calcium/calmodulin-dependent kinase inhibitors 21 . Our method could identify the potential for deleterious pharmacokinetic interactions with oxaliplatin prior to clinical studies. In this way, this in vitro assessment will complement trial design and endpoints we recently proposed for the early clinical evaluation of investigational treatments for preventing oxaliplatin neurotoxicity 40 .
In conclusion, calcium and magnesium accelerate the in vitro degradation of oxaliplatin by binding to a monochloro-monooxalato ring-opened anionic intermediate. Kinetic analyses of in vitro oxaliplatin stability data predicted the contributions of calcium-, magnesium-and chloride-mediated degradation to the total in vivo clearance of oxaliplatin in patients. In vitro-in vivo extrapolation methods can be used in future studies for the in vitro prediction of potential effects on oxaliplatin clearance in vivo.
Materials and Methods
In vitro incubation studies. Oxaliplatin and Pt(DACH)Cl 2 were obtained from Sigma-Aldrich (St Louis, MO, USA). Hydroxyethylpiperazine-N'-2-ethane sulfonic acid ('HEPES') was obtained from Gibco-BRL Life Technologies (Grand Island, NY, USA). Powder sodium chloride (NaCl) and magnesium chloride (MgCl 2 ) anhydrous were obtained from Sigma Aldrich (St Louis, MO, USA). Calcium chloride (CaCl 2 ) was obtained from Riedel-de Haen AG (Germany). Methanol of chromatographic grade, triflic acid (98% reagent grade) was obtained from Sigma Aldrich (St Louis, MO, USA). All solutions and mobile phase were prepared using Milli-Q grade water (Millipore, Bedford, USA).
To study the stability of oxaliplatin in the presence of chloride, calcium and magnesium under physiological conditions, oxaliplatin (100 μM prepared in Milli-Q water) was incubated in water alone, NaCl (15, 50, and 150 mM), CaCl 2 (1.8, 37.5 and 75 mM), and MgCl 2 (1.8, 37.5 and 75 mM) in HEPES buffer at pH 7.3 and 37 °C. A temperature regulated water-bath (Julabo TW12, John Morris Scientific Ltd., Auckland) was used to maintain temperature during incubation. Samples for analysis were taken at 0, 5, 10, 20, 30, and 60 minutes then hourly thereafter until 8 hours. To detect oxaliplatin and its degradation product, Pt(DACH)Cl 2 , these incubation samples were analysed using a Hewlett Packard HP1200 HPLC online system. This included a binary pump, a degasser and an autosampler (Wilmington, DE, USA), a Waters µBondapak C 18 3.9 × 300 mm column (Waters, Massachusetts, USA) with a guard column (Phenomenex, Torrance, LA, USA). The UV detector used was Millipore Waters Lambda-max model 480 LC Spectrophometer (Millipore, Land Cove, Australia). The HPLC separations were performed at room temperature using a mobile phase containing 3% methanol in Milli-Q water (adjusted to pH 2.5 with triflic acid). The flow rate was 0.5 mL/min. The UV wavelength monitored was 210 nm with a reference of 550 nm. The injection volume of all samples was 50 µL. Data acquisition and processing were performed using HP4500 ChemStation and HP1200 Agilent ChemStation offline software B.04.01 (Agilent Technologies, Avodale, USA). The samples were analysed immediately after they were taken from the incubation solutions whenever possible, otherwise they were snap frozen using liquid nitrogen and thawed within a minute before being injected onto the HPLC for analysis to avoid continuation of degradation of oxaliplatin at higher temperatures. All samples from each incubation study were analysed on the same day using the same mobile phase. Concentrations of oxaliplatin and Pt(DACH)Cl 2 were determined by using their respective calibration curves to convert the areas under the chromatographic peaks to concentration values. The concentrations of the intermediate species were estimated from a mass balance after accounting for oxaliplatin and Pt(DACH)Cl 2 . The kinetics of degradation reactions were modelled as described below.
Clinical study. In our previously reported clinical study 24 , a randomised double-blind placebo-controlled design was used to evaluate the effects of calcium gluconate (1 g) and magnesium sulfate (1 g) (CaGluc/MgSO 4 ) infusions on the pharmacokinetics and acute neurotoxicity of oxaliplatin. Each patient undergoing oxaliplatin chemotherapy was given either CaGluc/MgSO 4 or placebo infusions immediately before and after oxaliplatin infusion on cycle 1 then the opposite study infusion on cycle 2. This study was approved by the Northern Y Regional Ethics Committee (approval number NTY/11/01/005) and was conducted in accordance with its guidelines and regulations. Informed consent was obtained from all study participants. The plasma pharmacokinetic samples were collected at 13 predefined times including at baseline, during and 3 hours post oxaliplatin infusion. The samples used for this current study were taken at baseline, 20 minutes post first CaGluc/MgSO 4 or placebo infusion, immediately prior and post second CaGluc/MgSO 4 or placebo infusions. The plasma was immediately prepared by centrifugation at 4 °C and 5000 G for 5 minutes, then snap-frozen using liquid nitrogen. The samples were stored at −80 °C until analysis. Plasma calcium (albumin adjusted) and magnesium concentrations were measured using Cobas 8000 modular analyser (Roche Diagnostics Ltd., Switzerland) at LabPlus, Auckland City Hospital (Auckland, New Zealand). Data were presented as measured values and the levels of calcium and magnesium were graded using Common Toxicity Criteria Adverse Effect (CTCAE) version 4. Plasma calcium and magnesium concentrations were compared between baseline and post CaGluc/MgSO 4 or placebo infusions by repeated measures one-way ANOVA analysis. Correlation between calcium and magnesium concentrations and observed oxaliplatin clearance for each patient obtained from our previous study 24 was assessed by Pearson correlation analysis. All statistical analyses were performed using PRISM 6, GraphPad, San Diego, USA.
Kinetic modelling. Kinetic analysis of oxaliplatin reactivity in the presence of calcium and magnesium was done using the mean concentration values for oxaliplatin and Pt(DACH)Cl 2 at each sampling time. Rate constants were obtained by least-square fitting the analytical expressions for the reaction scheme to the three species simultaneously ( Fig. 1 -unshaded area) , using the Solver function in Microsoft Excel with the three rate constants k 1 , k −1 , and k 2 as adjustable parameters. Estimates of the standard errors for these parameters were then obtained using a Jack-knife procedure.
To determine in vitro intrinsic clearance of oxaliplatin attributable to chloride-, calcium-and magnesium-mediated degradation, the following steps were undertaken: (1) AUC 0−infinity for oxaliplatin concentration versus time for each in vitro incubation experimental condition was calculated using non-compartmental analysis; (2) total in vitro clearance of oxaliplatin for each condition was calculated by dividing the amount of oxaliplatin in the incubation solution per unit volume by the corresponding AUC 0−infinity ; (3) oxaliplatin clearance attributable to calcium-and magnesium-mediated degradation was calculated by subtracting the clearance attributable to chloride from the total in vitro clearance value for each condition; (4) calculated values for oxaliplatin clearance attributable to these ions were then plotted against the concentrations of the corresponding ions in the incubation solution and analysed by linear regression; and (5) finally, the in vitro intrinsic clearance attributable to chloride, calcium and magnesium was taken from the slope of the linear regression fit to its data ( Table 2 and Supplementary Figure) .
To extrapolate in vitro kinetic data from the incubation studies to in vivo oxaliplatin clearance attributable to plasma chloride, calcium and magnesium, a scaling factor was applied to the calculated intrinsic clearance for each of chloride, calcium and magnesium ions. The approach to scaling used in our study was a modified version of those used in the microsomal in vitro-in vivo extrapolation methods 32 . We used the estimated extracellular fluid (ECF) contents of chloride, calcium and magnesium in each patient. First, total body water was estimated as 60% of body weight in men and 50% in women, and the ECF volume was estimated as 40% of total body water. The ECF content of chloride, calcium and magnesium was then calculated by multiplying the measured plasma concentrations of these ions by the estimated ECF volume in each patient. Finally, in vivo clearance of oxaliplatin mediated by each of chloride, calcium and magnesium was calculated using the following formula: in vivo CL = in vitro CL int x ECF content, where units for CL = L/h; CL int = L/h/mmol; and ECF content = mmol).
